Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia by Cillóniz, Catia et al.
RESEARCH ARTICLE
Twenty-year trend inmortality among
hospitalized patients with pneumococcal
community-acquired pneumonia
Catia Cillóniz1, Adamantia Liapikou2, Ignacio Martin-Loeches3, Carolina Garcı́a-Vidal4,
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There is only limited information on mortality over extended periods in hospitalized patients
with pneumococcal community-acquired pneumonia (CAP). We aimed to evaluate the 30-
day mortality and whether is changed over a 20-year period among immunocompetent
adults hospitalized with pneumococcal CAP.
Methods
We conducted a retrospective observational study of data that were prospectively collected
at the Hospital Clinic of Barcelona of all adult patients hospitalized with diagnosis of pneu-
mococcal CAP over a 20-year period. To aid analysis, results were divided into four periods
of 5 years each (1997–2001, 2002–2006, 2007–2011, 2012–2016). The primary outcome
was 30-day mortality, but secondary outcomes included intensive care unit (ICU) admission,
lengths of hospital and ICU-stays, ICU-mortality, and need of mechanical ventilation.
Results
From a cohort of 6,403 patients with CAP, we analyzed the data for 1,120 (17%) adults with
a diagnosis of pneumococcal CAP. Over time, we observed decreases in the rates of alco-
hol consumption, smoking, influenza vaccination, and older patients (age65 years), but
increases in admissions to ICU and the need for non-invasive mechanical ventilation. The
overall 30-day mortality rate was 8% (95% confidence interval, 6%–9%; 84 of 1,120
patients) and did not change significantly between periods (p = 0.33). Although, we
observed a decrease in ICU-mortality comparing the first period (26%) to the second one
(10%), statistical differences disappeared with adjustment (p0.38).
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Conclusion
Over time, 30-day mortality of hospitalized pneumococcal CAP did not change significantly.
Nor did it change in the propensity-adjusted multivariable analysis. Since mortality in pneu-
mococcal pneumonia has remained unaltered for many years despite the availability of anti-
microbial agents with proven in vitro activity, other non-antibiotic strategies should be
investigated.
Introduction
Community-acquired pneumonia (CAP) continues to have high global morbidity and mortal-
ity rates, and is associated with considerable health costs[1,2]. Some recent published studies
have reported that the incidence of CAP has risen in the last decade[3,4], with an increase in
the rate of hospitalization. However, the trend in CAP mortality over recent decades is more
controversial, and it was recently stated that mortality in patients hospitalized for CAP has
declined over time[5–7]. Many clinical guidelinesfor CAP recommended by professional soci-
eties have been published since the early 1990s [8]. The aim of creating the guidelines was to a
large extent to bring together all the data on CAP and to provide a tool for the management of
CAP patients, since guidelines offer a means of standardizing care. The first set of guidelines
for CAP was published by ATS in 1993[8]; other guidelines were subsequently published,
updating the information with the results of new published studies on CAP, including IDSA
1998[9], ATS 2001[10], and the ATS/IDSA Joint Guidelines in 2007[11]. Two previous studies
have demonstrated reductions in mortality after guideline implementation: one in hospitalized
CAP[12]] and the other in severe CAP[13]. In fact, mortality has declined for a variety of con-
ditions over recent decades, including for sepsis, myocardial infarction, and stroke[14,15], sug-
gesting that better clinical management and improved healthcare are responsible[5–7].
Streptococcus pneumoniae (pneumococcus) remains the most common pathogen in CAP
[16,17], being associated with significant disease burden and a more severe disease course that
requires more medical resources compared with non-pneumococcal CAP[18]. In Catalonia,
the study setting, vaccination with 23-valent polysaccharide pneumococcal vaccine (PPV23)
has been recommended for high-risk and older adults since the early 2000s[19]. The 7-valent
pneumococcal conjugate vaccine (PCV7)was licensed in Spain for children In 2001, and it was
replaced by the 13-valent pneumococcal conjugate vaccine (PCV13) in 2010[20]. In Catalonia
in 2007 the estimated coverage of PCV7 was 47%, and the estimated coverage of PCV13 in
2013 was 55%[21,22]. However, except in the case of children with selected risk factors these
vaccines were not financed by the Catalan Public Health System until July 2016, and were only
available in the private sector. In Spain, the vaccines were not introduced into the recom-
mended calendar until January 2017. Finally, in late 2012, the PCV13 was introduced for
adults. A recent population-based cohort study involving more than two million people aged
over 50 in Catalonia which investigated the clinical effectiveness of PCV13 vaccination in pre-
venting hospitalization from pneumonia observed no clinical benefits from PCV13 vaccina-
tion. However, since in that study PCV13 coverage was low, vaccination was not randomized,
and follow-up time was limited, the results must be interpreted with caution[23].
In a large homogeneous cohort of critically ill patients with pneumococcal CAP, Mongar-
don et al.[24] observed that septic shock occurred in 84% and that mechanical ventilation was
required for 77%. The authors highlighted that, despite adequate antimicrobial therapy, pneu-
mococcal pneumonia still has high early mortality (29%).
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We hypothesized that mortality among patients hospitalized with pneumococcal CAP had
decreased over time because of improvements in early detection, antibiotic therapy, clinical
management, support bundles and improvement of health care systems. Thus, we aimed to
analyze 30-day mortality rate and the trend in mortality for pneumococcal CAP in a large hos-
pitalized adult population over a 20-year period. We also analyzed the main factors related to
overall mortality from pneumococcal CAP.
Patients andmethods
Study design
This was a retrospective observational study of data that were prospectively collected over 20
years in the Hospital Clinic, Barcelona. All adults with a clinical diagnosis of S. pneumoniae
pneumonia between January 1996 and December 2016 were included. To aid analysis, we
divided the study population into four cohorts by time period: 1997–2001, 2002–2006, 2007–
2011, and 2012–2016. For the purpose of publication the Ethics Committee of the Hospital
Clinic of Barcelona approved the study (Register: 2009/5451), and the need for written
informed consent was waived because of the non-interventional design.
Patients
We included all adults with a clinical diagnosis of pneumococcal pneumonia, including those
coming from nursing homes. We excluded patients with active tuberculosis or immunosup-
pression, including those taking>20 mg/day of prednisone (or daily equivalent) for at least 2
weeks, those receiving cytotoxic therapy, those known to have human immunodeficiency
virus infection.
Data collection, evaluation, and microbiological diagnosis
Demographic variables, comorbidities, and physiological parameters were collected in the
emergency department within 24 hours of admission. We also calculated the pneumonia
severity index (PSI), the CURB-65 (Consciousness, Urea, Respiratory rate, Blood pressure,
65 years old), and the sequential organ failure assessment (SOFA) scores at admission
[25–27]. During hospitalization, we recorded whether the patients had complications such
as multilobar infiltration, pleural effusions, acute respiratory distress syndrome(ARDS)
[28]], septic shock[29], or acute renal failure[30]. Further details are reported elsewhere
[17].
The etiology of pneumococcal pneumonia was determined by positive results in any of the
following: valid sputum culture; valid blood culture; pleural fluid and transthoracic needle
aspiration cultures; urinary antigen for S. pneumoniae; bacterial growth exceeding 103, 104, or
105 colony forming units (CFU)/mL in protective brush sample, bronchoalveolar lavage cul-
tures or tracheobronchial aspirate, respectively. Definition and additional details are shown in
Supplementary Material.
Primary and secondary outcomes
The primary outcome was 30-day mortality, and the secondary outcomes were the lengths of
hospital and ICU stays, admission to ICU, mortality in ICU, and need for mechanical ventila-
tion. Early mortality was defined as the mortality in the first 72 hours of admission and late
mortality was defined as the mortality after 72 hours to 30 days of admission.
Twenty-year trend in mortality in pneumococcal CAP
PLOSONE | https://doi.org/10.1371/journal.pone.0200504 July 18, 2018 3 / 16
Statistical analysis
We report the number and percentage of patients for categorical variables, the mean and stan-
dard deviation (SD) for normally distributed data, and the median and interquartile range
(IQR) for non-normally distributed data. To reduce the variability and random noise in year-
by-year data we divided the study into four time periods of five years each, defining 1997–2001
as the reference period. We estimated the overall 30-day mortality and the mortality in each of
the four periods, reporting them with 95% confidence intervals (CIs)[31]. Trends in associated
factors were analyzed using the Mantel–Hansel test for categorical variables and linear regres-
sion for continuous variables. Time to 30-day mortality was analyzed by Kaplan–Meier sur-
vival curves and compared using the Gehan–Breslow–Wilcoxon test. Cox proportional hazard
regression analyses[32] were performed to determine the influence of risk factors on the
30-day mortality. First, each risk factor was tested individually (see Methods in Supplementary
Material the full list of variables). Second, a propensity score (PS)[33] was developed for
empiric antibiotic use because antibiotic therapy were not randomly administered and could
have resulted in confounding and selection bias[34]. Finally, the scores, admission period, and
empiric antibiotic therapy were incorporated in the multivariable Cox regression model to
predict 30-day mortality, together with all risk factors showing an association in the univari-
able analyses by stepwise backward elimination (pin< 0.05, pout > 0.10). We calculated the
hazard ratios (HRs) and their 95% CIs. We calculated the area under the receiver operating
characteristic curve (AUC) for the multivariable model to predict 30-day mortality. Internal
validity of the prediction model was assessed by ordinary nonparametric bootstrapping with
1000 bootstrap samples and bias-corrected, accelerated 95% CIs[35]. Also, to determine the
influence of the risk factors on ICUmortality, the analyses were repeated on the subset of
patients admitted to ICU.
We used multiple imputation method for missing data for handling missing data in multi-
variable analyses[36]. The level of significance was set at 005 (two-tailed). All analyses were
performed with IBM SPSS Statistics 230 (Armonk, New York).
Results
Patients’ characteristics
Of the 6,403 patients with CAP admitted during the study period, 1,120 (18%) were diagnosed
with pneumococcal pneumonia and included in the study “Fig 1”. Our cohort comprised 694
males (62%) and 426 females (38%), with a mean (SD) age of 66.9 (17.7) years; notably, 701
(63%) were aged65 years.
Changes in patients’ characteristics over time
The main clinical characteristics of the study population are summarized by study period in
“Table 1”. There were no differences in sex between periods, but there were differences in the
distribution of cases by age, smoking status, and alcohol consumption, which were signifi-
cantly higher in the first period compared with later periods.
Regarding severity, there was a progressive increase in presentations with ARDS (4% in the
first period to 8% in the last period; p = 0.026) and patients with septic shock (9% in the first
period to 15% in the last period; p = 0.005).
The prevalence of pneumococcal CAP did not change significantly over time, only varying
between 39% and 42% (p = 0.98) “Table 2”. From 2002, 167 of 420 invasive isolates (40%) were
available for serotyping, and the percentages of cases covered by the pneumococcal conjugate
vaccine (PCV13) decreased from 94% in the second period to 56% in the last period
Twenty-year trend in mortality in pneumococcal CAP
PLOSONE | https://doi.org/10.1371/journal.pone.0200504 July 18, 2018 4 / 16
(p = 0.001). Regarding empiric antibiotic therapy, we observed no differences in prescriptions
of monotherapy and combination therapy between periods. The adequacy of antibiotic ther-
apy was similar among periods (97%).
Clinical outcomes
The most frequent causes of death were acute respiratory failure secondary to pneumonia
(54%; n = 45), multiorgan failure associated with septic shock (36%; n = 30), and acute cardiac
events related to pneumonia (8%; n = 7).
The overall 30-day mortality rate among all 1,120 patients was 8% (95% CI, 6%–9%;
n = 84). By subgroup, the 30-day mortality rates were as follows. In the 701 patients aged65
years, it was 10% (95% CI, 8%–12%; n = 69) compared with 4% (95% CI, 2%–5%; n = 15) in
the 419 patients aged<65 years (p< 0.001). In the 406 cases with invasive pneumococcal CAP
it was 10% (95% CI, 7%–13%; n = 40) compared with 6% (95% CI, 4%–8%; n = 36) in the 579
patients with non-invasive pneumococcal CAP (p = 0.035). Finally, the 30-day mortality
among 815 patients hospitalized to conventional wards was 4% (95% CI, 2%–5%; n = 30), but
this increased to 18% (95% CI, 13%–22%; n = 53) among the 302 patients admitted to ICU
(p< 0.001).
The 30-day mortality rate also changed with the number of comorbidities. In 779 patients
with at least one comorbidity, the rate was 9% (95% CI, 7%–11%; n = 71) compared with 4%
(95% CI, 2%–6%; n = 13) among 338 healthy patients (p = 0.002). As expected, compared with
the 30-day mortality of 7% (95% CI, 5%–9%; n = 75) among the 1,080 patients receiving ade-
quate antibiotic therapy, mortality increased to 25% (95% CI, 10%–40%; n = 8) among the 32
patients receiving inadequate antibiotic therapy (p< 0.001).
The frequency of mortality in the first 72 hours of admission (1.4% in the first period to
1.5% in the last period; p 0.89) and the frequency of mortality after 72 hours to 30 days (7% in
the first period to 8% in the last period; p 0.33) did not change over time. Outcomes by study
period are shown in “Table 3”.
Fig 1. Flow chart of study population.
https://doi.org/10.1371/journal.pone.0200504.g001
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Age, mean (SD), years 67.4 (16.4) 66.9 (18.0) 65.9 (18.2) 67.6 (18.4) 0.82
Age65 years, n (%) 194 (68) 215 (63) 168 (58) 124 (61) 0.029
Male sex, n (%) 205 (72) 186 (55) 173 (60) 130 (64) 0.095
Current smoker, n (%) 99 (35) 96 (28) 80 (28) 47 (23) 0.006
Current alcohol consumer, n (%) 72 (26) 60 (18) 47 (17) 30 (15) 0.002
Previous antibiotic, n (%) 31 (11) 61 (18) 41 (16) 32 (16) 0.18
Influenza vaccine, n (%) 20 (32) 127 (42) 118 (47) 49 (25) 0.030
Pneumococcal vaccine, n (%) 11 (18) 45 (15) 40 (16) 36 (19) 0.51
Previous inhaled corticosteroids, n (%) 57 (20) 67 (20) 77 (27) 33 (17) 0.87
Previous systemic corticosteroids, n (%) 12 (12) 27 (8) 9 (3) 10 (5) 0.004
Previous episode of pneumonia (last year), n (%) 28 (11) 71 (21) 26 (10) 14 (7) 0.012
Comorbidities, n (%)a 221 (78) 240 (71) 187 (64) 131 (64) <0.001
Chronic respiratory disease 172 (61) 160 (47) 127 (45) 65 (33) <0.001
COPD 138 (49) 98 (29) 74 (26) 39 (20) <0.001
Asthma 9 (3) 24 (7) 16 (6) 7 (4) 0.88
Bronchiectasis 9 (3) 7 (2) 11 (4) 1 (1) 0.28
Otherb 16 (6) 31 (9) 26 (9) 18 (9) 0.15
Chronic cardiovascular disease 47 (17) 52 (15) 41 (14) 11 (6) 0.001
Diabetes mellitus 55 (19) 78 (23) 41 (14) 40 (20) 0.46
Neurological disease 32 (11) 42 (13) 46 (17) 35 (18) 0.016
Chronic renal disease 23 (8) 17 (5) 21 (7) 17 (9) 0.64
Chronic liver disease 30 (11) 23 (7) 15 (5) 16 (8) 0.15
Nursing-home, n (%) 9 (3) 16 (5) 24 (8) 10 (5) 0.093
Creatinine, mg/dL, median (IQR) 1.1 (0.9; 1.4) 1.2 (1; 1.6) 1 (0.8; 1.5) 1.2 (0.9; 1.7) 0.47
C-reactive protein, mg/dL, median (IQR) 169 (85; 296) 221 (111; 317) 242 (147; 308) 246 (148; 290) 0.59
PaO2/FiO2, median (IQR) 276 (229; 314) 281 (243; 319) 267 (218; 301) 266 (203; 308) 0.002
SOFA score, median (IQR) 2 (2; 4) 3 (2; 4) 2 (1; 3) 2 (1; 3) <0.001
SOFA score5, n (%)c 53 (19) 54 (16) 35 (12) 12 (8) 0.002
PSI score, median (IQR) 102 (80; 127) 100 (77; 126) 100 (75; 120) 105 (80; 125) 0.43
PSI risk class IV–V, n (%)d 173 (62) 188 (60) 107 (55) 59 (64) 0.57
CURB-65 risk class 3–5, n (%)e 74 (26) 88 (26) 51 (20) 31 (21) 0.090
Pneumococcal bacteremia, n (%) 104 (39) 113 (41) 93 (37) 70 (41) 0.90
Invasive pneumococcal pneumonia, n (%) 111 (41) 121 (42) 101 (39) 73 (42) 0.98
Pleural effusion, n (%) 49 (17) 59 (17) 68 (24) 30 (16) 0.64
Multilobar, n (%) 75 (26) 97 (29) 76 (26) 66 (32) 0.28
ARDS, n (%) 12 (4) 13 (4) 19 (7) 16 (8) 0.026
Acute renal failure, n (%) 80 (28) 115 (34) 83 (29) 72 (36) 0.21
Septic shock, n (%) 27 (9) 34 (10) 50 (17) 31 (15) 0.005
Empiric antibiotic therapy, n (%)
Monotherapy 50 (18) 81 (24) 60 (21) 33 (16) 0.63
Fluoroquinolones 8 (3) 68 (20) 50 (17) 19 (9) 0.025
β-lactams 34 (12) 11 (3) 10 (3) 12 (6) 0.003
Other therapy 8 (3) 2 (1) 0 (0) 2 (1) 0.020
Combination therapies 232 (82) 259 (76) 230 (79) 169 (84) 0.63
β-lactams plus macrolides 185 (66) 148 (44) 87 (30) 97 (48) <0.001
β-lactams plus fluoroquinolones 4 (1) 84 (25) 119 (41) 57 (28) <0.001
(Continued)
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The overall 30-day mortality rate did not change significantly between periods (p = 0.33),
ranging from 8% in the first period to 10% in the last period “Fig 2”. Kaplan–Meier survival
curves depicting 30-day mortality rates as a function of period are shown in “Fig 3”. There was
a progressive increase in patients requiring ICU admission (20% in the first period to 33% in
the last period; p< 0.001) and non-invasive mechanical ventilation (NIV) (0% in the first
period to 7% in the last period; p< 0.001). The use of invasive mechanical ventilation did not
change between the four periods. ICU mortality was 26% in the first period, it dropped to 10%
in the second period, and remained stable thereafter (p = 0.023). However, after adjusted by
propensity-adjusted multivariable analysis, study period was not associated with ICU
mortality.
In the subgroup of patients receiving NIV, ICU mortality changed non-significantly from
0% in the first period to 9% in the last period (p = 0.23). By Kaplan–Meier analysis, time to
death in the ICU and time to death of patients receiving NIV in the ICU did not differ signifi-
cantly between periods (p = 0.17 and p = 0.76, respectively) (S1 Fig).
Factors associated with 30-Day mortality and ICUmortality
The univariable Cox regression analysis revealed several variables to be significantly associated
with 30-day mortality “Table 4”. Among these, age65 years, diabetes mellitus, SOFA score
5, and requirement for mechanical ventilation (non-invasive and invasive) were indepen-











Other combination therapies 43 (15) 27 (8) 24 (8) 15 (7) 0.005
Appropriate empiric treatment, n (%) 274 (97) 328 (97) 280 (97) 198 (99) 0.63
Abbreviations: ARDS indicates acute respiratory distress syndrome; COPD = chronic obstructive pulmonary disease; CURB-65 = Consciousness, Urea, Respiratory rate,
Blood pressure, 65 years old; IQR, interquartile range; PSI, pneumonia severity index; PaO2/FiO2 = arterial oxygen tension to inspired oxygen fraction ratio; SD,
standard deviation; SOFA, sequential organ failure assessment. Percentages calculated on non-missing data.
a May have>1 comorbid condition.
b Other respiratory diseases include sequelae of pulmonary tuberculosis, pulmonary hypertension, and interstitial lung disease.
c Optimal cut-off value to predict 30-day mortality using ROC curves.
d Stratified according to 30-day risk mortality for community-acquired pneumonia: risk classes I–III (90 points) have low mortality and risk classes IV–V (>90 points)
have the highest mortality.
e Stratified according to 30-day risk mortality for community-acquired pneumonia: risk classes 0–2 have low mortality and risk classes 3–5 have the highest mortality.
https://doi.org/10.1371/journal.pone.0200504.t001










Urinary antigen test for pneumococcus 111/120 (93) 222/255 (87) 199/238 (84) 131/168 (78) 0.001
Blood culture 104/268 (39) 113/279 (41) 93/252 (37) 70/170 (41) 0.90
Pleural fluid culture 12/37 (32) 8/32 (25) 13/48 (27) 7/23 (30) 0.81
Sputum culture 131/189 (69) 61/197 (31) 59/155 (38) 35/96 (37) 0.001
Bronchoalveolar aspirate 26/42 (62) 8/26 (31) 16/42 (38) 6/19 (32) 0.005
Data are shown as number of patients with pneumonia due to Streptococcus pneumoniae (pneumococcus) / number of patients for each microbiological examination
performed (%).
https://doi.org/10.1371/journal.pone.0200504.t002
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30-day mortality, n (%) 24 (8) 16 (5) 24 (8) 20 (10) 0.33
Length of hospital stay, median (IQR), days 8 (5; 11) 8 (5; 12.5) 9 (6; 12) 8 (6; 13) 0.070
ICU admission, n (%) 57 (20) 78 (23) 100 (34) 67 (33) <0.001
ICU mortality, n (%)a 15 (26) 8 (10) 11 (11) 7 (10) 0.023
Length of stay in ICU, median (IQR), daysa 12 (8; 24) 14 (9; 27) 11 (8; 17.5) 12 (8; 19) 0.20
Mechanical ventilation, n (%)b 0.78
Not ventilated 249 (87) 292 (89) 217 (84) 139 (86) 0.31
Non-invasive 0 14 (4) 17 (7) 11 (7) <0.001
Invasive 36 (13) 23 (7) 26 (10) 11 (7) 0.11
Abbreviations: ICU, intensive care unit; IQR, interquartile range. Percentages calculated on non-missing data.
a 57 patients in the 1997–2001 period, 78 patients in the 2002–2006 period, 100 in the 2007–2011 period, and 67 patients in the 2012–2016 period were used to calculate
the percentages and the medians (IQR).
b Patients who initially received non-invasive ventilation but subsequently needed intubation were included in the invasive mechanical ventilation group.
https://doi.org/10.1371/journal.pone.0200504.t003
Fig 2. Rate of 30-day mortality per period.
https://doi.org/10.1371/journal.pone.0200504.g002
Twenty-year trend in mortality in pneumococcal CAP
PLOSONE | https://doi.org/10.1371/journal.pone.0200504 July 18, 2018 8 / 16
Period of admission was not significantly associated with 30-day mortality after adjustment for
potential confounders.
The AUC was 0.70 (95% CI, 0.64–0.76) for the model predictive of 30-day mortality (S2
Fig). The sensitivity was 63% (95% CI, 52%–74%), specificity was 68% (95% CI, 65%–71%),
positive predictive value was 14% (95% CI, 10%–17%), negative predictive value was 96% (95%
CI, 94%–97%), positive likelihood ratio was 1.97 (95% CI, 1.64–2.38), and negative likelihood
ratio was 0.54 (95% CI, 0.41–0.72). Internal validation of the Cox regression model by boot-
strapping demonstrated robust results for all variables included in the model, with small 95%
CIs around the original coefficients (S1 Table).
The univariable Cox regression analysis revealed several variables significantly associated
with ICU mortality among the subset of patients admitted to the ICU “Table 5”. Notably, age
65 years and requirement for invasive mechanical ventilation were independently associated
with ICU mortality in the propensity-adjusted multivariable analysis. Again, however, period
of admission was not significantly associated with ICUmortality after adjustment for potential
confounders. The AUC was 0.70 (95% CI, 0.62–0.78) for the model predictive of ICUmortality
(S3 Fig). The sensitivity was 85% (95% CI, 73%–97%), specificity was 49% (95% CI, 43%–
55%), positive predictive value was 21% (95% CI, 14%–27%), negative predictive value was
96% (95% CI, 92%–99%), positive likelihood ratio was 1.67 (95% CI, 1.40–1.99), and negative
Fig 3. Kaplan-Meier analysis on the effect of period on time to death.
https://doi.org/10.1371/journal.pone.0200504.g003
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likelihood ratio was 0.30 (95% CI, 0.14–0.63). Internal validation of the Cox regression model
by bootstrapping demonstrated robust results for all the variables included in the model, with
small 95% CIs around the original coefficients (S2 Table).
Discussion
There are three main findings to this study. First, it was striking that the 30-day mortality of
patients hospitalized for pneumococcal CAP did not change significantly over time (this
Table 4. Significant univariable and multivariable Cox regression analyses for the prediction of 30-day mortality.
Variable Univariablea Multivariableb
HR 95% CI P-value HR 95% CI P-value
Period of admissionc 0.12 0.12
1997–2001 1.00 – – 1.00 – –
2002–2006 0.54 0.29 to 1.02 0.060 1.67 0.15 to 18.95 0.68
2007–2011 0.97 0.55 to 1.71 0.93 4.03 0.20 to 81.23 0.36
2012–2016 1.17 0.65 to 2.12 0.60 3.09 0.46 to 20.97 0.25
Age65 years 2.83 1.62 to 4.95 <0.001 2.93 1.63 to 5.27 <0.001
Previous systemic corticosteroids 1.51 0.94 to 2.42 0.090 – – –
Chronic renal disease 2.58 1.43 to 4.67 0.002 – – –
Chronic liver disease 2.10 1.14 to 3.87 0.017 – – –
Neurologic disease 1.61 1.00 to 2.60 0.052 – – –
Diabetes mellitus 2.07 1.26 to 3.39 0.004 1.68 0.99 to 2.85 0.054
SOFA score5d 7.22 4.70 to 11.08 <0.001 3.91 2.17 to 7.03 <0.001
Invasive pneumococcal pneumonia 1.63 1.04 to 2.55 0.034 – – –
Empiric antibiotic therapye 0.001 0.11
Beta-lactams monotherapy 1.14 0.49 to 2.63 0.76 1.08 0.44 to 2.63 0.87
Fluoroquinolones monotherapy 0.51 0.22 to 1.19 0.12 1.52 0.59 to 3.94 0.38
Beta-lactams plus fluoroquinolones 0.96 0.51 to 1.81 0.90 1.32 0.62 to 2.81 0.48
Beta-lactams plus macrolides 0.35 0.18 to 0.68 0.002 0.59 0.29 to 1.21 0.15
Other 1.00 – – 1.00 – –
Adequate empiric antibiotic therapy 0.22 0.11 to 0.45 <0.001 – – –
ICU admission 5.17 3.31 to 8.02 <0.001 – – –
Mechanical ventilationf <0.001 <0.001
Not ventilated 1.00 – – 1.00 – –
Non-invasive 5.86 2.69 to 12.78 <0.001 2.95 1.22 to 7.16 0.017
Invasive 8.85 5.58 to 14.02 <0.001 4.07 2.40 to 6.88 <0.001
Abbreviations: CI indicates confidence interval; HR, hazard ratio; ICU, intensive care unit; SOFA, sequential organ failure assessment. Data are shown as estimated HRs
(95% CIs) of the explanatory variables in the 30-day mortality group. The HR is the ratio of hazards (probability of death) in two groups, given that the patient has
survived up to a specific time. The P-value is based on the null hypothesis that all HRs relating to an explanatory variable equal unity (no effect).
a The variables analyzed in the univariable analysis were: age, gender, tobacco use, alcohol consumption, influenza and pneumococcal vaccination, previous systemic
and inhaled corticosteroids, prior antibiotic treatment, chronic pulmonary disease, chronic cardiovascular disease, chronic renal disease, chronic liver disease, diabetes
mellitus, neurological disease, SOFA score, invasive disease pneumonia, adequate empiric antibiotic therapy, ICU admission, and mechanical ventilation.
b Adjusted for the propensity score.
c The p-value corresponds to differences between the four groups (1997–2001, 2002–2006, 2007–2011, or 2012–2016).
d Optimal cut-off value to predict 30-day mortality using ROC curves.
e The p-value corresponds to differences between the five groups (beta-lactams monotherapy, fluoroquinolones monotherapy, beta-lactams plus fluoroquinolones, beta-
lactams plus macrolides, or other).
f The p-value corresponds to differences between the three groups (not ventilated, non-invasive, or invasive).
https://doi.org/10.1371/journal.pone.0200504.t004
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included early and late mortality). Second, although we observed a progressive increase in the
number of patients admitted to ICU and receiving NIV between periods, the mortality of
patients receiving NIV in ICU did not change over that time. Third, mortality in ICU fell from
26% in the first study period to 10% in the second period, and remained stable thereafter; how-
ever, when we adjusted by propensity-adjusted multivariable analysis, study period was not
associated with higher mortality.
Recently, there have been few studies about the changes in CAP-related mortality over time
[5,6,37], with only limited information about the 30-day mortality in patients hospitalized
with pneumococcal CAP over study periods of a decade or longer[24].
This study is the first, to our knowledge, to describe trends in 30-day mortality over a 20
year period in patients hospitalized with confirmed pneumococcal CAP. It was remarkable
that we found no evidence of 30-day mortality for pneumococcal CAP decreasing in hospital-
ized adult patients over that period. Nevertheless, our results are consistent with those of epi-
demiological research in Canada (excluding Quebec) over a 6 year period[24]. In that study,
Table 5. Significant univariable and multivariable cox regression analyses for the prediction of icu mortality.
Variable Univariablea Multivariableb
HR 95% CI P-value HR 95% CI P-value
Period of admissionc 0.10 0.38
1997–2001 1.00 – – 1.00 – –
2002–2006 0.36 0.15 to 0.85 0.020 2.72 0.04 to 211.36 0.65
2007–2011 0.54 0.25 to 1.19 0.13 7.56 0.03 to 1,688.48 0.46
2012–2016 0.50 0.20 to 1.23 0.13 1.96 0.06 to 67.07 0.71
Age65 years 2.34 1.17 to 4.67 0.016 2.27 1.08 to 4.79 0.031
SOFA score5d 2.68 1.40 to 5.13 0.003 – – –
Empiric antibiotic therapye 0.21 0.29
Beta-lactams monotherapy 1.66 0.45 to 6.14 0.45 0.75 0.18 to 3.04 0.68
Fluoroquinolones monotherapy 1.13 0.31 to 4.19 0.85 2.84 0.63 to 12.76 0.17
Beta-lactams plus fluoroquinolones 0.58 0.25 to 1.35 0.21 0.98 0.33 to 2.90 0.97
Beta-lactams plus macrolides 0.50 0.21 to 1.19 0.12 0.58 0.23 to 1.42 0.23
Other 1.00 – – 1.00 – –
Adequate empiric antibiotic therapy 0.37 0.17 to 0.79 0.011 – – –
Mechanical ventilationf 0.001 0.017
Not ventilated 1.00 – – 1.00 – –
Non-invasive 2.07 0.58 to 7.33 0.26 2.21 0.60 to 8.23 0.24
Invasive 4.97 2.04 to 12.08 <0.001 3.76 1.51 to 9.37 0.005
Abbreviations: CI indicates confidence interval; HR, hazard ratio; ICU, intensive care unit; SOFA, sequential organ failure assessment. Data are shown as estimated HRs
(95% CIs) of the explanatory variables in the ICU mortality group. The HR is the ratio of hazards (probability of death) in two groups, given that the patient has survived
up to a specific time. The P-value is based on the null hypothesis that all HRs relating to an explanatory variable equal unity (no effect).
a The variables analyzed in the univariable analysis were: age, gender, tobacco use, alcohol consumption, influenza and pneumococcal vaccination, previous systemic
and inhaled corticosteroids, prior antibiotic treatment, chronic pulmonary disease, chronic cardiovascular disease, chronic renal disease, chronic liver disease, diabetes
mellitus, neurological disease, SOFA score, invasive disease pneumonia, adequate empiric antibiotic therapy, and mechanical ventilation.
b Adjusted for the propensity score.
c The p-value corresponds to differences between the four groups (1997–2001, 2002–2006, 2007–2011, or 2012–2016).
d Optimal cut-off value to predict 30-day mortality using ROC curves.
e The p-value corresponds to differences between the five groups (beta-lactams monotherapy, fluoroquinolones monotherapy, beta-lactams plus fluoroquinolones, beta-
lactams plus macrolides, or other).
f The p-value corresponds to differences between the three groups (not ventilated, non-invasive, or invasive).
https://doi.org/10.1371/journal.pone.0200504.t005
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the authors reported that case-fatality rates from pneumococcal pneumonia remained stable
(11.6% to 12.3%) between 2004 and 2010, although they did report a decrease in the incidence
of CAP due to S. pneumoniae, which they attributed to vaccination programs. However, they
relied entirely on retrospective data extracted from an administrative database, which would
be subject to potential biases, especially in the case of S. pneumoniae diagnosis. By contrast,
our data acquisition was prospective and relied on a confirmed microbiological diagnosis of S.
pneumoniae. In addition, our 30-day mortality was 3%–4% lower than that reported by the
Canadian group.
Although we did not observe a fall in 30-day mortality over time, an interesting finding was
the decrease in the presence of comorbidities, and also the decrease in the proportion of cur-
rent smokers over time. One possible explanation is the change of pneumococcal serotypes
over the course of the study period. Since the beginning of 2000, serotype evolution in pneu-
mococcus has been in constant progress, influenced by the introduction of pneumococcal con-
jugate vaccines (PCVs)[21,38]. Despite the effectiveness of the PCV in reducing the burden of
invasive pneumococcal disease, the incidence of complicated pneumonia[39] is rising because
of the emergence of non-vaccine serotypes. This increase does not appear to be related to the
concurrent increase in penicillin-resistant S. pneumoniae but does seem related to the intro-
duction of virulent clones expressing non-vaccine serotypes, especially serotype 1[40]. On the
other hand, we cannot rule out the possible effect of ambient air pollution on on the incidence
of pneumococcal infections[41–43] as reported by a Spanish study of 619 cases of pneumococ-
cal infections which found that fossil fuel-derived pollutants (SO2, NO), and dry and cold air
increased the incidence of pneumococcal infections[43].
We observed an increase in patients admitted to ICU, as well increases in the proportions
of patient with ARDS, with septic shock, and requiring NIV. These data are consistent with
results of a UK study in which it was reported that a growing number of CAP cases have
required ICU admission in the last 20 years, regardless of age groups[44]. The reason for the
increase in ICU admission is probably related to a better knowledge among clinicians of the
definitions of severe CAP in international guidelines[11,45].
ICU mortality was 26% in the first period, dropped to 10% in the second period, and then
remained stable. However, we could not confirm this downward trend and subsequent stabili-
zation when adjusting the results by propensity-adjusted multivariable analysis. We think that
the reduction in ICU mortality between the first and the second periods of our study was
related to the 2001 and 2007 CAP guidelines[10,11], recommendations from the Surviving
Sepsis campaign[29], and the implementation of early initiation of the first antibiotic dose[46].
There are two previous studies, one in hospitalized CAP[12] and another one in severe CAP
[13], that have demonstrated reductions in mortality after guideline implementation.
It is noteworthy that our data are in partial disagreement with the results of Gattarello et al.
[37], who conducted a matched case-control study (80 cases and 80 controls) comparing the
periods 2000–2002 and 2008–2013. They reported a 15% decrease in mortality among patients
with pneumococcal pneumonia admitted to the ICU, and that early antibiotic administration
and combination antibiotic therapy were independently associated with better outcomes.
However, there were important differences with our study: (a) we included the data for 1,120
patients and the study by Gattarello et al.[37] included only 160 patients; (b) more than 60% of
the patients (n = 701) were aged65 years in our cohort, whereas only 33% (n = 54) were
aged65 years in their cohort; and c) antibiotic therapy did not affect mortality in our study
because most patients received adequate empirical antibiotic therapy.
The major strengths of our study are the large cohort, long study period, consecutive enroll-
ment, and inclusion of only cases with microbiologically confirmed pneumococcal CAP. How-
ever, a potential limitation of the study is that data were collected from a single academic
Twenty-year trend in mortality in pneumococcal CAP
PLOSONE | https://doi.org/10.1371/journal.pone.0200504 July 18, 2018 12 / 16
teaching hospital in Spain, which has extensive experience in the management of CAP; conse-
quently, it may not be possible to extrapolate our results to patients admitted to other types of
hospitals in other countries. Other potential limitations are the changes in the diagnosis, treat-
ment, and prevention of CAP during the 20 years of study for which we did not account. How-
ever, our antibiotic treatment protocol has not changed substantially for CAP during these
years, and we have followed the 1993, 1998, 2001, and 2007 guidelines for managing CAP[8–
11].
In conclusion, we observed increases in the rates of patients admitted to ICU and in the
rates of ARDS, septic shock, and requirement for NIV. We did not find a decrease in mortality
from pneumococcal CAP. Given that mortality from pneumococcal pneumonia has not
changed for many years despite treatment with appropriate antimicrobial therapy, there is a
growing need for non-antibiotic strategies to be investigated.
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Carolina Garcı́a-Vidal, Albert Gabarrús, Adrian Ceccato, Daniel Magdaleno, Josep Mensa,
Francesc Marco, Antoni Torres.
References
1. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia
among adults in Europe. Thorax. 2012 Jan; 67(1):71–9. https://doi.org/10.1136/thx.2009.129502
PMID: 20729232
2. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy,
all-causemortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic anal-
ysis for the Global Burden of Disease Study 2015. Lancet Lond Engl. 2016 Oct 8; 388(10053):1459–
544.
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munity-acquired pneumonia and its relation to severity. Thorax. 2011 Apr; 66(4):340–6. https://doi.org/
10.1136/thx.2010.143982 PMID: 21257985
18. Pletz MW, von BaumH, van der Linden M, Rohde G, Schütte H, Suttorp N, et al. The burden of pneu-
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